The medical technology firm sets 2026 revenue growth target of at least 8% after reporting Q1 2026 results.
TELA Bio guided for at least 8% revenue growth in 2026, citing progress in its commercial strategy reset. The company reported early proof points in Q1 2026 that its plan is delivering results, though specific figures were not disclosed.
For Q2 2026, TELA expects revenue of approximately $20.0M. The guidance follows a period of strategic adjustments aimed at improving market positioning and operational efficiency.
Management highlighted confidence in the trajectory but did not provide additional financial details or market reaction data.